Epidermal growth factor receptor (EGFR) is the most frequently mutated receptor in glioblastoma (57% of cases), followed by platelet-derived growth factor receptor (PDGFRA) (13%), fibroblast growth factor receptor (FGFR) (3.2%), and c-MET (1.6%) [40,41,42]. Here, PDGFRA is linked to glioblastoma.